Breaking News

Everest Medicines, Singapore’s EDDC Enter Global Licensing Agreement for COVID Oral Antivirals

Everest gains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

p.p1 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’} span.s1 {letter-spacing: 0.0px} Everest Medicines and Singapore’s Experimental Drug Development Centre (EDDC) entered a global licensing agreement under which Everest will obtain exclusive worldwide rights to develop, manufacture and commercialize EDDC’s series of viral 3C-like (3CL) protease inhibitors as potentially best-in-class COVID-19 oral antiviral treatments. EDDC is Singapore’s nationa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters